News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS) Appoints Merck & Co., Inc. (MRK) Executive As Cancer Chief


6/2/2014 8:22:25 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Novartis announces the appointment of Bruno Strigini as President of Novartis Oncology

Basel, June 1, 2014 - Novartis announced today the appointment of Bruno Strigini, as President of Novartis Oncology, effective June 1, 2014.

Mr. Strigini joins Novartis from Merck & Co where he most recently served as president for Europe/Canada, a region comprising 37 countries with over 10,000 associates. With 25 years of experience in pharmaceuticals, animal health, OTC and vaccines leading in both international and local roles, he has a global perspective on the healthcare industry, with expertise across diverse geographies, including both mature and emerging markets.

During his career, Bruno Strigini has held increasingly senior executive positions in a number of companies, such as Schering-Plough, UCB-Celltech and SmithKline Beecham. Previous roles have included President of International Operations, President of Japan and Asia-Pacific, and Senior Vice-President and Head of Global Marketing & Business Development, as well as Managing Director positions in New Zealand, the UK and Spain.

He is a member of the Executive Committee for the European Federation of Pharmaceutical Industries & Associations (EFPIA), as well as a member of the Académie Nationale de Pharmacie in France. Bruno holds an MBA from IMD, Lausanne (Switzerland), a doctorate degree in pharmacy from the University of Montpellier (France), and a master's degree in microbiology from Heriot-Watt University (UK).

Disclaimer
The foregoing release contains forward-looking statements that can be identified by words such as "joins," or similar terms, or by express or implied discussions regarding the potential impact of Mr. Strigini's' leadership on the Novartis Oncology business. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any particular results will be achieved under Mr. Strigini's leadership. In particular, management's expectations could be affected by, among other things, the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected manufacturing issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES